The two companies have entered into a collaboration agreement regarding the continued development of Zyneyro’s peptide- and AAV-based treatment of chronic pain conditions.
The agreement with Zyneyro is a cooperation agreement that means that Zyneyro and CombiGene share the project’s costs and revenues equally.
“The concept of being able to give the pain-relieving peptide directly to patients with temporary pain conditions and to use AAV vectors that instruct the body to establish the pain-relieving mechanism on its own in chronic pain conditions is extremely attractive.”
“I am very impressed with Zyneyro’s work in the field of pain management,” says Jan Nilsson, CEO of CombiGene. “The concept of being able to give the pain-relieving peptide directly to patients with temporary pain conditions and to use AAV vectors that instruct the body to establish the pain-relieving mechanism on its own in chronic pain conditions is extremely attractive. All drug development is associated with risks. There are never any guarantees that a project will be successful. Zyneyro has shown impressive preclinical data from the studies they have conducted. It will now be extremely stimulating to take this project forward through the preclinical phase together with our colleagues at Zyneyro.”
An upfront of DKK 5 million
According to the agreement CombiGene will pay Zyneyro an upfront of DKK 5 million in connection with the signing of the agreement. CombiGene has furthermore committed to pay an additional maximum of DKK 11.4 million in continued development support towards clinical Phase 1. The peptide-based treatment is expected to be ready for the first human dosing in 2025, while the AAV-based treatment will need additional development time to reach the same point.
“In CombiGene we have found the optimal partner for this project. CombiGene has a highly experienced drug development team that builds on and complements Zyneryo’s very strong competencies in the early drug development phase. In collaboration with CombiGene, Zyneyro will have unique access to potential pharmaceutical partners with the resources and expertise to take the drugs to patients – in addition to the partners Zyneyro itself has been in contact with,” says Zyneyro’s CEO Peter Horn Møller.
Photo of Jan Nilsson: CombiGene